Global biopharmaceutical company Bristol Myers Squibb has acquired MyoKardia Inc. in an all-cash transaction for approximately $13.1 billion. MyoKardia Inc., a biomedical company founded in 2013, develops small molecule therapeutics that address key clinical needs for patients with genetic heart disease. The genetic heart diseases targeted by MyoKardia are hypertrophic...
